IMMUNOHISTOCHEMISTRY, PS2

The IHC – PS2 (Trefoil Factor 1 / TFF1) test is an immunohistochemistry-based diagnostic assay used to detect PS2 protein expression in tissue samples. PS2, also known as Trefoil Factor 1 (TFF1), is a protein whose expression is regulated by estrogen and is commonly associated with hormone-responsive breast tissue and breast tumors.

This test is primarily used in pathology and oncology to evaluate breast cancer, particularly tumors that may respond to hormonal therapy. PS2 expression is often associated with estrogen receptor (ER)-positive breast cancers and can provide additional information about tumor biology, hormone responsiveness, and prognosis.

The IHC PS2 test helps pathologists identify estrogen-regulated protein expression within tumor cells and may support treatment planning when used alongside established breast cancer biomarkers such as ER, PR, HER2, and Ki-67.

Benefits of the Test

• Helps assess hormone-responsive breast tumors
• Supports breast cancer characterization
• Provides information about estrogen-related tumor activity
• Assists in prognosis evaluation
• Helps guide hormone therapy decisions

Why Doctors Recommend This Test

Doctors recommend the IHC PS2 test when evaluating breast cancer and hormone-sensitive tumors. It is commonly used in:

• Breast cancer biomarker assessment
• Hormone receptor-positive tumor evaluation
• Prognostic studies in breast cancer
• Tumor biology characterization
• Oncology pathology investigations

PS2 is frequently evaluated together with ER, PR, HER2, Ki-67, and P53 markers to provide a more comprehensive understanding of tumor behavior and treatment response.

Preparation Before Test

No special preparation is required for this test. Important considerations include:

• The test is performed on a biopsy or surgical tissue sample
• No fasting is required
• No medication restrictions are generally necessary
• Clinical history and pathology findings may support interpretation

Normal Reporting Time

The typical turnaround time is 3 to 5 working days, depending on specimen processing and laboratory workflow.

Who Should Take This Test

• Patients diagnosed with breast cancer
• Individuals with hormone receptor-positive tumors
• Patients requiring detailed tumor profiling
• Cases requiring prognosis assessment
• Oncology patients undergoing immunohistochemistry evaluation

The IHC PS2 test is a useful adjunct marker in breast cancer pathology. By identifying estrogen-regulated protein expression, it helps clinicians better understand tumor biology and optimize treatment planning.

Clinical Significance

PS2 immunostaining is commonly used in the evaluation of:

• Estrogen receptor-positive breast cancer
• Hormone-responsive breast tumors
• Breast carcinoma prognosis assessment
• Tumor response prediction studies
• Breast cancer biomarker panels

PS2 positivity is generally associated with hormone-sensitive tumors and may correlate with a more favorable response to endocrine therapy.